期刊
ARCHIVES OF INTERNAL MEDICINE
卷 166, 期 8, 页码 902-908出版社
AMER MEDICAL ASSOC
DOI: 10.1001/archinte.166.8.902
关键词
-
资金
- NCRR NIH HHS [M01-RR01066, M01 RR001066] Funding Source: Medline
- NIDDK NIH HHS [F32 DK068902, P30 DK040561-11, P30 DK040561, F32 DK068902-01] Funding Source: Medline
Background: Adipose-derived cytokines, including tumor necrosis factor alpha, may contribute to the inflammation that occurs in the metabolic syndrome. We investigated the effects of inhibition of tumor necrosis factor alpha with etanercept in patients with the metabolic syndrome. Methods: Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers ( including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined. Results: Baseline characteristics were similar between the groups. Two subjects dropped out of each group, and etanercept was well tolerated throughout the study. The C-reactive protein levels decreased significantly in the treated compared with the placebo group (-2.4 +/- 0.4 vs 0.5 +/- 0.7 mg/ L;P <. 001). Adiponectin levels rose significantly in the etanercept group compared with the placebo group (0.8 +/- 0.4 vs -0.3 +/- 0.3 mu g/mL; P=.03). Fibrinogen levels decreased (-68 +/- 16 vs -2 +/- 31 mg/ dL [-2.0 +/- 0.47 vs -0.06 +/- 0.91 mu mol/ L]; P=. 04) and interleukin 6 levels tended to decrease (- 1.2 0.8 vs 0.5 +/- 0.5 ng/L; P=.07) in the etanercept-treated subjects compared with placebo, respectively. No changes occurred in body composition parameters or insulin sensitivity, but high-density lipoprotein levels tended to decrease in the etanercept group (- 1 +/- 1 vs 2 +/- 1 mg/ dL [-0.03 +/- 0.03 vs 0.05 +/- 0.03 mmol/ L]; P=. 06) compared with the placebo group. Conclusions: Etanercept reduces C-reactive protein levels and tends to improve other inflammatory cardiovascular risk indexes in patients with the metabolic syndrome. Etanercept may interrupt the inflammatory cascade that occurs with abdominal obesity. Further, longer-term studies are needed to determine the effects of tumor necrosis factor alpha inhibition on cardiovascular disease in patients with the metabolic syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据